Profile: Ironwood Pharmaceuticals Inc (IRWD.O)
27 May 2016
Ironwood Pharmaceuticals, Inc., incorporated on January 5, 1998, is a biotechnology company. The Company's products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. The Company's product, linaclotide, which is available in the United States under the brand name LINZESS, and is available in European countries under the brand name CONSTELLA. The Company in collaboration with Astellas Pharma Inc. (Astellas) is engaged in advancing linaclotide colonic release, a second-generation product candidate with the potential to improve abdominal pain relief in adult IBS-C patients, as well as in patients with additional GI, disorders where lower abdominal pain is a predominant symptom, such as IBS-mixed (IBS-M), ulcerative colitis and diverticulitis. In addition, the Company is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD).
The Company is conducting a randomized, double-blind, placebo-controlled, multi-site Phase III clinical trial in the United States to assess the efficacy and safety of linaclotide in an approximately 72-microgram (mcg) dose in adult patients with CIC. The Company has completed nonclinical studies and has initiated two Phase II clinical pediatric studies in IBS-C patients age 7 to 17 and functional constipation patients age 6 to 17. The Company is conducting a Phase II clinical study evaluating linaclotide in adult patients with Opioid-induced Constipation (OIC). The Company in collaboration with AstraZeneca AB (AstraZeneca) is co-developing linaclotide in China, Hong Kong and Macau. The Company is conducting a randomized, placebo-controlled, multi-site Phase IIa clinical study evaluating whether IW-9179 can provide symptomatic relief to adult patients with diabetic gastroparesis. Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD.
The Company is advancing development programs targeting soluble guanylate cyclase (sGC), and exploring its utility in vascular and fibrotic diseases. The Company has two sGC development candidates, which include IW-1973 and IW-1701. The Company is initiated an open-label, single dose, crossover stage, and a randomized, double-blind, placebo-controlled, multiple-ascending-dose stage Phase Ib clinical study of IW-1973. The Company is also initiated a randomized, double-blind, placebo-controlled, single-ascending-dose Phase Ia clinical study of IW-1701.
Ironwood Pharmaceuticals Inc
301 Binney St
CAMBRIDGE MA 02142-1030
Company Web Links
- BRIEF-Ironwood Pharmaceuticals Q1 gaap loss per share $0.09
- AstraZeneca sells U.S. gout drug rights to Ironwood for up to $265 million
- UPDATE 1-AstraZeneca sells U.S. gout drug rights to Ironwood for up to $265 mln
- BRIEF-Ironwood, AstraZeneca enter U.S. licensing agreement for lesinurad
- CORRECTED-AstraZeneca to sell US rights for gout drug for up to $265 mln